Stem Cell Clinic

Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020

Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections

Read the original:
Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020

Immutep Granted European Patent for IMP761

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office.

View post:
Immutep Granted European Patent for IMP761

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy…

Continued here:
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy...

Radius Health, Inc.: Progress Since May 2020

WALTHAM, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor conferences. The key areas of activity included as part of its update are outlined below.

Link:
Radius Health, Inc.: Progress Since May 2020

SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020

Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections

See more here:
SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

BASEL, Switzerland, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis and in women with uterine fibroids. The data were presented in virtual oral and poster sessions during the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress, held October 17-21, 2020.

Read more:
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

The Quest for Blockbuster Drugs Continues

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire — 180 Life Sciences Corp. today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

See original here:
The Quest for Blockbuster Drugs Continues

Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders

Reports positive preclinical data in animal models Reports positive preclinical data in animal models

Follow this link:
Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders

Telo Genomics Announces Warrant Exercise Agreement

TORONTO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (OTC: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has engaged Leede Jones Gable Inc. and Mackie Research Corporation (the “Brokers”) to solicit and facilitate, on a commercially reasonable efforts basis, the exercise of warrants issued pursuant to the Company’s financing announced November 25th, 2019 (the “Warrants”). TELO has 8,677,500 Warrants outstanding with an exercise price $0.20 per share which expire on November 25th, 2020. In connection with the engagement, the Brokers will be paid a fee of 4% of the gross proceeds received by TELO from the exercise of the Warrants.

Read this article:
Telo Genomics Announces Warrant Exercise Agreement

Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™

--FDA feedback consistent with FDA’s preliminary communication in September----Company requesting meeting with FDA to discuss next steps required to resubmit the NDA--FREMONT, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, announced today that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA).

Go here to read the rest:
Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™